European Neuropsychopharmacology
Volume 20, Issue 5 , Pages 346-355 , May 2010

Outcomes of 1014 naturalistically treated inpatients with major depressive episode

  • Florian Seemüller

      Affiliations

    • Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Ludwig-Maximilians-University, Nussbaumstr. 7, 80336 Munich, Germany. Tel.: +49 89 5160 5846; fax: +49 89 5160 5774.
    • ,
  • Michael Riedel

      Affiliations

    • Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    • ,
  • Michael Obermeier

      Affiliations

    • Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    • ,
  • Michael Bauer

      Affiliations

    • Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Dresden, Technical University Dresden, Fetscherstr. 74, 01307 Dresden, Germany
    • ,
  • Mazda Adli

      Affiliations

    • Department of Psychiatry and Psychotherapy, Campus, Charité Mitte (CCM), Charitéplatz 1, 10117 Berlin, Germany
    • ,
  • Klaus Kronmüller

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Heidelberg, Voßstr. 2, 69115 Heidelberg, Germany
    • ,
  • Florian Holsboer

      Affiliations

    • Department of Psychiatry and Psychotherapy, Max Planck Institute of Psychiatry, Kraepelinstr. 2-7, 80804 Munich, Germany
    • ,
  • Peter Brieger

      Affiliations

    • Department of Psychiatry and Psychotherapy, Martin-Luther University Halle-Wittenberg, Julius-Kühn-Str.7, 06097 Halle, Germany
    • ,
  • Gerd Laux

      Affiliations

    • Department of Psychiatry and Psychotherapy, Inn-Salzach-Klinikum, Garbersee 7, 83512 Wasserburg, Germany
    • ,
  • Wolfram Bender

      Affiliations

    • Department of Psychiatry and Psychotherapy, Isar-Amper-Klinikum Munich East, Vockestr. 72, 85540 Haar, Germany
    • ,
  • Isabella Heuser

      Affiliations

    • Department of Psychiatry and Psychotherapy, Campus Charité Benjamin Franklin (CFB), Eschenallee 3, 14050 Berlin, Germany
    • ,
  • Joachim Zeiler

      Affiliations

    • Department of Psychiatry and Psychotherapy, Auguste-Viktoria-Krankenhaus, Rubensstr. 125, 12157 Berlin, Germany
    • ,
  • Wolfgang Gaebel

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Düsseldorf, Bergische Landstr. 2, 40629 Düsseldorf, Germany
    • ,
  • Eva Dichgans

      Affiliations

    • Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    • ,
  • Roland Bottländer

      Affiliations

    • Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    • ,
  • Richard Musil

      Affiliations

    • Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    • ,
  • Hans-Jürgen Möller

      Affiliations

    • Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany

Received 5 March 2009 ,Revised 6 November 2009 ,Accepted 26 November 2009.

References 

  1. American Psychiatric Association . Practice guideline for the treatment of patients with major depressive disorder (revision). Am. J. Psychiatry. 2000;157:1–45
  2. APA—American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders — DSM-IV-TR. 4th edition. 2000;Text Revision, Washington, DC
  3. Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J. Psychiatry Neurosci. 2002;27:250–257
  4. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J. Biol. Psychiatry. 2007;8:67–104
  5. Beasley CM, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann. Clin. Psychiatry. 1993;5:199–207
  6. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J. Clin. Psychiatry. 2004;65:1190–1196
  7. Cording C, Gaebel W, Spengler A. Die neue psychiatrische Basisdokumentation. In: Eine Empfehlung der DGPPN zur Qualitätssicherung im (teil-) stationären Bereich. [The new psychiatric basic documentation. A recommendation by the DGPPN for quality assurance in inpatient treatment]. Spektrum Psychiatrie Nervenheilkunde. 1995;p. 3–41
  8. Deutsche Gesellschaft, für Psychiatrie, P. u. N. . Praxisleitlinien in Psychiatrie und Psychotherapie, 5: Behandlungsleitlinien affektive Erkrankungen [Practice Guideline for the Treatment of Affective Disorders]. Darmstadt: Steinkopff; 2000;
  9. Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J. Clin. Epidemiol. 2003;56:968–976
  10. Guelfi JD, Corruble E. Methodological issues raised by clinical trials on dysthymia: assessment instruments and response criteria. Eur Psychiatry. 1997;12:183–189
  11. Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology National Institute of Mental Health, Rockville. 1976;MD revised
  12. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 1967;6:278–296
  13. Keller MB, Gelenberg AJ, Hirschfeld RM, Rush AJ, Thase ME, Kocsis JH, et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J. Clin. Psychiatry. 1998;59:598–607
  14. Lavori PW, Keller MB, Klerman GL. Relapse in affective disorders: a reanalysis of the literature using life table methods. J. Psychiatr. Res. 1984;18:13–25
  15. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987;334:1–100
  16. Moller HJ, Baldwin DS, Goodwin G, Kasper S, Okasha A, Stein DJ, et al. Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur. Arch. Psychiatry Clin. Neurosci. 2008;258(Suppl 3):3–233–23
  17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 1979;134:382–389382–389
  18. Oliver JP, Huxley PJ, Priebe S, Kaiser W. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Soc. Psychiatry Psychiatr. Epidemiol. 2004;32(2):76–83
  19. Priebe S, Gruyters T, Heinze M, Hoffmann C, Jakel A. [Subjective evaluation criteria in psychiatric care--methods of assessment for research and general practice]. Psychiatr. Prax. 1995;22(4):140–144
  20. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry. 2006;163:1905–1917
  21. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry. 2006;163:1905–1917
  22. Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch. Gen. Psychiatry. 2005;62:513–520
  23. Schneider F, Harter M, Brand S, Sitta P, Menke R, Hammer-Filipiak U, et al. Adherence to guidelines for treatment of depression in in-patients. Br. J. Psychiatry. 2005;187:462–469462–469
  24. Seemuller F, Riedel M, Obermeier M, Bauer M, Adli M, Mundt C, et al. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int. J. Neuropsychopharmacol. 2008;1–9
  25. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry. 2001;178:234–2341234–241
  26. Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch. Gen. Psychiatry. 2004;61:669–680
  27. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry. 2006;163:28–40
  28. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M. Strukturiertes Klinisches Interview für DSM-IV. Göttingen: Hogrefe; 1997;
  29. World Health Organization . The ICD-10 Classification of Mental and behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO; 1992;
  30. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am. J. Psychiatry. 2002;159:469–473

PII: S0924-977X(09)00276-4

doi: 10.1016/j.euroneuro.2009.11.011

European Neuropsychopharmacology
Volume 20, Issue 5 , Pages 346-355 , May 2010

Article Tools

* Image Usage & Resolution